Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)16.72
  • Today's Change-0.10 / -0.59%
  • Shares traded63.93k
  • 1 Year change+35.49%
  • Beta0.8602
Data delayed at least 15 minutes, as of Feb 13 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Medios AG, formerly Crevalis Capital AG, is a Germany-based company offering solutions in pharma industry. The Company covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. It operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.

  • Revenue in EUR (TTM)2.01bn
  • Net income in EUR22.03m
  • Incorporated1999
  • Employees999.00
  • Location
    Medios AGHeidestrasse 9BERLIN 10557GermanyDEU
  • Phone+49 30 232566800
  • Fax+49 30 232566801
  • Websitehttps://medios.group/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SIGA Technologies Inc145.13m62.75m409.69m46.006.562.396.482.821.031.032.402.840.80690.742523.633,744,558.0034.8827.7239.2133.3676.2986.0643.2344.287.24--0.0037.70-0.856138.99-13.01--7.85--
Medios AG2.01bn22.03m426.46m999.0019.190.79087.110.21190.87140.871478.9821.142.1721.5212.292,006,511.002.382.593.373.099.666.531.090.86211.314.760.27650.005.5129.51-33.295.1524.73--
Cuorips Inc1.96m-4.22m430.97m56.00--15.56--219.59-93.30-93.3043.60607.390.06563.33238.006,351,607.00-14.20---14.62--76.69---216.57--36.81--0.00--658.40---1.92------
Nxera Pharma Co Ltd158.36m-33.90m433.42m374.00--1.20--2.74-68.13-68.13318.44725.520.19361.474.5776,737,970.00-4.14-1.71-4.63-1.8571.1784.07-21.41-10.932.55-11.730.4902--125.8724.2832.74--40.57--
Shanghai Fudan Forward S&T Co Ltd80.65m-14.52m434.97m1.41k--5.73--5.39-0.1744-0.17440.97210.91580.42680.80159.29467,663.00-7.83-3.33-14.36-5.8232.0539.99-18.35-7.670.4787-12.630.4378---5.05-14.35-509.42---18.59--
Data as of Feb 13 2026. Currency figures normalised to Medios AG's reporting currency: Euro EUR

Institutional shareholders

28.90%Per cent of shares held by top holders
HolderShares% Held
Janus Henderson Investors UK Ltd.as of 17 Oct 20251.63m6.39%
Axxion SA (Luxembourg)as of 01 Jan 20261.55m6.09%
SEB Investment Management AB (Denmark)as of 02 Jan 20251.20m4.70%
Paladin Asset Management Investmentaktiengesellschaft TGVas of 01 Jan 2026613.33k2.41%
Discover Capital GmbHas of 31 Oct 2025575.00k2.25%
Cr�dit Mutuel Asset Management SAas of 30 Oct 2025463.00k1.82%
Norges Bank Investment Managementas of 30 Jun 2025366.50k1.44%
HC Capital Advisors GmbHas of 31 Oct 2025346.70k1.36%
Kreissparkasse Biberachas of 28 Nov 2025315.00k1.24%
GS&P Kapitalanlagegesellschaft SAas of 30 Jun 2025310.00k1.22%
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.